Floseal与鼻腔填塞治疗前鼻孔出血的成本效果评价
该研究采用Markov模型,从加拿大公共资助医疗体系视角比较Floseal与鼻腔填塞治疗前鼻孔出血的终身成本与健康产出。结果显示Floseal策略成本更高($2,067)但获得更多QALY(0.27),在支付意愿阈值超过$120,000/QALY时成本效果概率达99%。结论认为在加拿大医疗体系中Floseal相比鼻腔填塞具有成本效果。
要点
- Floseal较鼻腔填塞成本高$2,067但多获得0.27个QALY。
- 支付意愿阈值>$120,000/QALY时Floseal成本效果概率达99%。
- 结果对贴现率、Floseal成本和鼻腔填塞成本高度敏感。
核心结论
- 在加拿大医疗体系中,Floseal治疗前鼻孔出血相比鼻腔填塞似乎是一种具有成本效果的治疗选择。
研究设计与样本
- 成本-效用分析,采用Markov模型,从公共资助医疗体系视角比较Floseal与鼻腔填塞的终身成本和健康产出,周期长度1年。
- Floseal和填塞的疗效来自已发表文献,单位成本来自医院病例成本核算系统,医生费用取自安大略省医师服务受益表。
- 结果表示为每获得一个质量调整生命年(QALY)的增量成本,并进行一系列单因素敏感性和概率敏感性分析。
主要发现
- 从公共资助医疗体系视角,Floseal治疗策略比鼻腔填塞成本更高($2,067)且QALY更高(0.27)。
- 结果对贴现率、Floseal成本和鼻腔填塞成本高度敏感。
- 概率敏感性分析提示,若支付意愿阈值大于$120,000/QALY,Floseal治疗具有成本效果的概率达到99%。
关键数值与推荐
- 增量成本为$2,067,增量QALY为0.27(Floseal vs 鼻腔填塞)。
- 支付意愿阈值大于$120,000/QALY时,Floseal成本效果概率为99%。
临床怎么用
- 在加拿大公共资助医疗体系中,对于前鼻孔出血,当支付意愿阈值超过$120,000/QALY时,Floseal相比鼻腔填塞可能具有成本效果。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: To evaluate the cost-effectiveness of Floseal, a topically applied hemostatic agent, and nasal packing for the management of epistaxis in Canada. STUDY DESIGN: Outcomes research, a cost-utility analysis. METHODS: We developed a Markov model to compare the costs and health outcomes of Floseal with nasal packing over a lifetime horizon from the perspective of a publicly funded healthcare system. A cycle length of 1 year was used. Efficacy of Floseal and packing was sought from the published literature. Unit costs were gathered from a hospital case costing system, whereas physician fees were extracted from the Ontario Schedule of Benefits for Physician Services. Results were expressed as an incremental cost per quality-adjusted life year (QALY) gained. A series of one-way sensitivity and probabilistic sensitivity analyses were performed. RESULTS: From the perspective of a publicly funded health are system, the Floseal treatment strategy was associated with higher costs ($2,067) and greater QALYs (0.27) than nasal packing. Our findings were highly sensitive to discount rates, the cost of Floseal, and the cost of nasal packing. The probabilistic sensitivity analysis suggested that the probability that Floseal treatment is cost-effective reached 99% if the willingness-to-pay threshold was greater than $120,000 per QALY gained. CONCLUSIONS: Prior studies have demonstrated Floseal to be an effective treatment for anterior epistaxis. In the Canadian healthcare system, Floseal treatment appears to be a cost-effective treatment option compared to nasal packing for anterior epistaxis. LEVEL OF EVIDENCE: 2c Laryngoscope, 1778-1782, 2018.
引用
- Le A, Thavorn K, Lasso A, et al. Economic evaluation of floseal compared to nasal packing for the management of anterior epistaxis. Laryngoscope. 2018. PMID: 29314035. doi:10.1002/lary.27081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。